tiprankstipranks
Advertisement
Advertisement

NPCE Stock Latest News

NeuroPace announces FDA approval of ECoG Assistant
The FlyNeuroPace announces FDA approval of ECoG Assistant
8d ago
NPCE
NeuroPace price target raised to $20 from $19 at H.C. Wainwright
PremiumThe Fly
NeuroPace price target raised to $20 from $19 at H.C. Wainwright
22d ago
NPCE
Neuropace Warns Cybersecurity Threats to Intracranial EEG Data Could Hit Operations, Reputation and Growth
PremiumCompany Announcements
Neuropace Warns Cybersecurity Threats to Intracranial EEG Data Could Hit Operations, Reputation and Growth
23d ago
NPCE
NeuroPace Earnings Call Highlights RNS Growth Momentum
PremiumCompany Announcements
NeuroPace Earnings Call Highlights RNS Growth Momentum
23d ago
NPCE
NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers
PremiumRatings
NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers
24d ago
NPCE
NeuroPace reports Q1 EPS (20c), consensus (23c)
PremiumThe FlyNeuroPace reports Q1 EPS (20c), consensus (23c)
24d ago
NPCE
NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M
Premium
The Fly
NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M
24d ago
NPCE
NeuroPace announces publication of 3-year results from RNS System PAS
Premium
The Fly
NeuroPace announces publication of 3-year results from RNS System PAS
1M ago
NPCE
NeuroPace Earnings Call Highlights Growth And AI Push
PremiumCompany Announcements
NeuroPace Earnings Call Highlights Growth And AI Push
2M ago
NPCE
NeuroPace assumed with an Overweight at Wells Fargo
PremiumThe Fly
NeuroPace assumed with an Overweight at Wells Fargo
3M ago
NPCE
NeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
PremiumRatings
NeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
3M ago
NPCE
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
PremiumCompany Announcements
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
3M ago
NPCE
NeuroPace reports Q4 EPS (8c), consensus (17c)
PremiumThe FlyNeuroPace reports Q4 EPS (8c), consensus (17c)
3M ago
NPCE
NeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M
Premium
The Fly
NeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M
3M ago
NPCE
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.94M
Premium
The Fly
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.94M
3M ago
NPCE
NPCE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
NPCE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
NPCE
NeuroPace price target raised to $19 from $18 at H.C. Wainwright
PremiumThe Fly
NeuroPace price target raised to $19 from $18 at H.C. Wainwright
4M ago
NPCE
Morning Movers: L3Harris Technologies jumps after DoW investment
PremiumThe Fly
Morning Movers: L3Harris Technologies jumps after DoW investment
5M ago
BK
CAH
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
PremiumThe Fly
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
5M ago
NPCE
NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
PremiumThe FlyNeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
5M ago
NPCE
NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M
Premium
The Fly
NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M
5M ago
NPCE
NeuroPace Initiated With Buy on Breakthrough RNS Label Expansion Opportunity and Strong NAUTILUS Efficacy Data
Premium
Ratings
NeuroPace Initiated With Buy on Breakthrough RNS Label Expansion Opportunity and Strong NAUTILUS Efficacy Data
6M ago
NPCE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >